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Abstract
Bluetongue virus (BTV) belongs to the genus Orbivirus within the family Reoviridae. The development of vector-based
vaccines expressing conserved protective antigens results in increased immune activation and could reduce the number of
multiserotype vaccinations required, therefore providing a cost-effective product. Recent recombinant DNA technology has
allowed the development of novel strategies to develop marker and safe vaccines against BTV. We have now engineered
naked DNAs and recombinant modified vaccinia virus Ankara (rMVA) expressing VP2, VP7 and NS1 proteins from BTV-4.
IFNAR
(2/2) mice inoculated with DNA/rMVA-VP2,-VP7-NS1 in an heterologous prime boost vaccination strategy generated
significant levels of antibodies specific of VP2, VP7, and NS1, including those with neutralizing activity against BTV-4. In
addition, vaccination stimulated specific CD8
+ T cell responses against these three BTV proteins. Importantly, the vaccine
combination expressing NS1, VP2 and VP7 proteins of BTV-4, elicited sterile protection against a lethal dose of homologous
BTV-4 infection. Remarkably, the vaccine induced cross-protection against lethal doses of heterologous BTV-8 and BTV-1
suggesting that the DNA/rMVA-VP2,-VP7,-NS1 marker vaccine is a promising multiserotype vaccine against BTV.
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Introduction
Bluetongue (BT) is a non-contagious, insect-transmitted disease
of wild and domestic ruminants that is caused by bluetongue virus
(BTV). BTV infection of ruminants occurs throughout much of
the tropical and recently also the temperate climate regions of the
world, coincident with the distribution of specific species of
Culicoides biting midges that are the biological vectors of the virus
[1,2]. BTV is the prototype member of the genus Orbivirus of the
family Reoviridae [3]. After the incursion of BTV into European
Mediterranean countries in 1998, vaccination was used in an effort
to minimize direct economic losses to animal production, reduce
virus circulation and allow safe movements of animals from
endemic areas [4]. Live attenuated vaccines are available for
different serotypes of BTV. These cell culture adapted viruses,
which can also replicate in the vaccinated host, generate significant
viremia and neutralizing antibodies, with long-lasting and
serotype-specific protection in the recovered animal. Despite their
relatively crude nature, inactivated BTV-8 and BTV-1 vaccines
are now being used in Europe and they have been effective in
preventing further outbreaks of both serotypes.
Although this demonstrates the central importance of vaccina-
tion in strategies to combat the spread of BTV, both the modified
live and inactivated vaccines are serotype specific. This not only
requires a different vaccine for each serotype, but it also invalidates
established serological assays (e.g. ELISA) for routine surveillance
and import/export testing, since they cannot distinguish between
infected and vaccinated animals. Moreover, live BTV vaccines can
also become virulent [5] and generate viremia levels that are
sufficient for the transmission of the virus to feeding midges [6].
Indeed, several outbreaks of bluetongue in Europe since 1998
were caused by live vaccine strains of BTV-2, 6, 9, 11 and 16.
Finally, the circulation of the vaccine strains also results in the
exchange of genome segments (reassortment) with field strains,
leading to the emergence of novel viruses [7].
Recombinant viral vaccines offer good immunogenicity associ-
ated with a replicating virus without the possibility of reassortment.
Several prototypic vaccines have been developed and tested with
promising results. The capsid proteins VP2, VP5 and VP7 of
BTV-1 were expressed in vaccination experiments with a
recombinant vaccinia virus, eliciting neutralizing antibody re-
sponses and protection against challenge infection [8]. Capripox
viruses individually expressing VP2, VP7, NS1 and NS3 of BTV-2
completely prevented viremia in goats challenged with the
heterologous serotype three weeks after combined application,
but their protective efficacy in sheep was much lower [9]. In
another study with homologous virus, a canarypox virus vector
expressing both outer capsid proteins of BTV-17 fully protected
sheep against virulent challenge [10]. A capripox virus expressing
VP7 of BTV-1 even afforded partial protection against a highly
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we have described a heterologous prime-boost vaccination strategy
against BTV using DNA and recombinant MVA expressing VP2,
VP5, and VP7 proteins of BTV-4. We showed that vaccination
with these DNA/rMVA of mice deficient in type I IFN receptor
(IFNAR2/2), an animal model for BTV infection established in
our laboratory [12,13], were protected against lethal challenge
with BTV-4. Moreover, we demonstrated that vaccination
induced neutralizing antibodies and T cell mediated immunity
[14]. In addition, Virus-like particles (VLPs) of BTV have been
produced in insect cell culture using the baculovirus-based protein
expression system. VLPs elicit strong and long-lasting immune
responses stimulating both B- and T-cell responses [15].
The study of the interaction of BTV with the immune system
has showed that neutralizing antibodies [16] and cytotoxic T
lymphocytes (CTLs) [17,18] have a role in protective immunity
against BTV [17,18,19,20]. However, in some instances inacti-
vated whole virus vaccines protect against virulent challenge
without inducing any measurable neutralizing antibody response.
On another hand, the degree of immunity after BTV infection
does not always correlate with the level of neutralizing antibodies,
even against homologous challenge [21], suggesting the involve-
ment of other factors in the outcome of subsequent infections.
Little is known about the location of antigenic determinants for T
cells. However, important variations in the protein targets of CTL
exist between individuals and host species [22]. VP2 and NS1 are
major CTL immunogens in sheep, while VP3, VP5, and VP7
seem to be less immunodominant [23,24]. However, it has been
demonstrated that a BTV-VP7 recombinant capripoxvirus
induces significant protective immune responses via a cell-
mediated mechanism against homologous challenge. In addition,
inactivated BTV-1 vaccine was able to prime sheep to elicit
increased cytokine response (Interferon (IFN)c, Interleukin (IL)-2
and IL-12) against heterologous BTV-23 stimulation in vitro [25].
These studies showed a potential role of CTLs in conferring partial
heterotypic immunity to BTV-infection in sheep [11,26]. Overall,
these studies demonstrate that the development of vectored
vaccines expressing conserved protective antigens results in
increased immune activation and would reduce the number of
multiserotype vaccinations required.
In this study, we describe a heterologous prime boost
vaccination strategy against BTV using DNA/rMVA expressing
VP2, VP7, and NS1 proteins (DNA/rMVA-VP2,-VP7, -NS1) of
BTV-4. We show that vaccination with these DNA/rMVA of
mice deficient in type I IFN receptor (IFNAR
(2/2)), achieves
protective homotypic and heterotypic immunity and protection
against homologous and heterologous infection with BTV-4,
BTV-8 and BTV-1. These results demonstrate that a rational
strategy for the design of effective, cross-protective vaccines
involves the combination of antigenic determinants of BTV.
Results
Evaluation of protein expression in cells tranfected with
cDNAs or infected with recombinant MVAs expressing
VP2, VP7, and NS1 proteins from BTV-4
In order to evaluate the expression of the BTV-4 recombinant
VP2, VP7, and NS1 proteins from pcDNA3 and rMVAs vectors
in transfected BHK-21 and infected DF-1 cells, respectively,
transient expression studies using immunofluorescence microscopy
(IFA) were performed. Fluorescence was observed on BHK-21
cells transfected with pcDNA3-VP2, pcDNA3-VP7, and pcDNA3-
NS1 but not on cells transfected with the control plasmid pcDNA3
(Fig. 1). Expression of VP2, VP7, and NS1 proteins was also
observed in DF-1 cells infected with rMVA-VP2, rMVA-VP7, and
rMVA-NS1, respectively, but not in control MVA infected cells
(Fig. 1). These data confirm the efficient expression of the proteins
from BTV-4 cloned in the DNA and MVA vaccine vectors used
for immunization of IFNAR
(2/2) mice.
Heterologous prime boost immunization with pcDNA3-
VP2/pcDNA3-VP7/pcDNA3-NS1 and rMVA-VP2/rMVA-
VP7/rMVA-NS1 protects IFNAR
(2/2) mice against
homologous BTV-4 infection
Adult IFNAR
(2/2) mice were immunized first with pcDNA3-
VP2, pcDNA3-VP7 and pcDNA3-NS1 by intramuscular injec-
tion. After two weeks, mice were inoculated intraperitoneally with
a booster of rMVA-VP2, rMVA-VP7 and rMVA-NS1. Two
weeks after the second immunization, immunized and control
IFNAR
(2/2) mice were challenged subcutaneously with 10
3 PFUs
of BTV-4. While all non-immunized animals died, 100% of the
immunized animals did not show clinical signs and were
completely protected against lethal challenge (Fig. 2). To analyze
whether the combination of the three antigens VP2, VP7 and NS1
is essential for a complete protection against the homologous
challenge with BTV-4, two groups of six adult IFNAR
(2/2) mice
Figure 1. Expression of the VP2, VP7 and NS1 BTV proteins.
Immunofluorescence microscopy using a mouse polyclonal antibody
against BTV-4 in BHK-21 cells transfected with pcDNA3, pcDNA3-VP2,
pcDNA3-VP7, or pcDNA3-NS1 plasmids and DF-1 cells infected with
rMVA, rMVA-VP2, rMVA-VP7, or rMVA-NS1.
doi:10.1371/journal.pone.0034735.g001
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and two weeks later, boosted with rMVA-VP2/VP7 or rMVA-
NS1, respectively. In both groups of mice, immunization delayed
the appearance of clinical signs and death of the animals upon
challenge with BTV-4. In the case of the IFNAR
(2/2) mice
immunized with vaccine vectors containing VP2 plus VP7, 32% of
the animals survived, while immunization with NS1 elicited
protection to only 16% of the mice (Fig. 2). These data confirm
that the three BTV antigens VP2, VP7, and NS1 are necessary for
the total protection against BTV-4 challenge.
The titers of infectious virus recovered in the blood after
challenge with BTV-4 were determined in IFNAR
(2/2) mice
immunized with pcDNA3-VP2/pcDNA3-VP7/pcDNA3-NS1
and rMVA-VP2/rMVA-VP7/rMVA-NS1, and in non-immu-
nized mice by plaque assay. No infectious viruses were detected in
the immunized mice; however, titers up to 2,2610
3 PFU/ml were
observed at 5 days post-challenge in non-immunized animals (data
not shown). In addition, the presence of the BTV genome in blood
of immunized and non-immunized IFNAR
(2/2) mice challenged
with BTV-4 was analyzed by RT-qPCR (Table 1). Non-
immunized mice (n=4) were positive for the BTV genome at
day three after BTV infection and viremia increased thereafter
until the death of the animal. In contrast, all the immunized mice
(n=6) were negative at all the days post-challenge analyzed
(Ct$38) indicating that protective immunity was achieved after
vaccination. These data confirm complete and sterile protection
against BTV-4 upon heterologous prime boost immunization by
using naked DNA and rMVA as vectors to express VP2, VP7 and
NS1 from BTV-4.
Generation of recombinant VP2, VP7, and NS1 proteins
from BTV-4 by using the baculovirus expression system
To analyse the humoral and cellular immune responses during
vaccination, the recombinant VP2, VP7, and NS1 BTV-4 proteins
were expressed by using the baculovirus expression system and
purified. H5 cells were infected with rBAC-VP2, rBAC-VP7, or
rBAC-NS1 and the BTV-4 protein expression was analyzed at 24,
48, and 72 h.p.i by immunoblot. The maximal expression levels of
the three proteins were observed at 48 and 72 h.p.i. (Fig. 3).
Proteins were purified as described in materials and methods and
used to develop ELISA systems that allow the detection of
antibodies specific of VP2, VP7, and NS1. In addition, the purified
recombinant BTV-4 proteins were used to stimulate splenocytes
from immunized mice to analyze the cellular response induced by
the vaccines.
Heterologous prime boost vaccination with pcDNA3/
rMVA expressing VP2, VP7, and NS1 induces humoral
response against these BTV-4 proteins
The presence in serum of specific antibodies to VP2, VP7, and
NS1 was analyzed at 14 and 28 days post infection (d.p.i). by
ELISA. Antibodies against VP2, VP7, and NS1 were observed at
14 d.p.i, indicating seroconversion. Furthermore, the level of
antibodies against these three BTV proteins was highly increased
Figure 2. Protection of VP2, VP7 and NS1 vaccinated IFNAR
(2/2)
mice against a lethal homologous BTV-4 challenge. Mice
(8 weeks old, 6 per group) were immunized twice by heterologous
prime boost vaccination with pcDNA3 and rMVA expressing VP2/VP7/
NS1 (&), VP2/VP7 (m), or NS1 (N) BTV-4 proteins (immunized, black line)
or pcDNA3 and MVA (¤) (non-immunized, dotted line), administered 2
weeks apart. Two weeks after immunization all mice were intravenously
inoculated with 10
3 PFUs of BTV-4 (lethal dose). Survival rates of
immunized and non-immunized IFNAR
(2/2) mice after inoculation with
BTV-4. The mice were observed every 24 h for 12 days.
doi:10.1371/journal.pone.0034735.g002
Table 1. Detection of BTV RNA in blood of immunized and
non-immunized IFNAR
(2/2) mice after challenge with BTV-4
by RT-qPCR_S5.
Animals Days post-challenge
35 7 9 1 1
C-1 33,98 {
C-2 38,79 25.98 {
C-3 23,1 {
C-4 33,65 {
I-1 neg. neg. neg. neg. neg.
I-2 neg. neg. neg. neg. neg.
I-3 neg. neg. neg. neg. neg.
I-4 neg. neg. neg. neg. neg.
I-5 neg. neg. neg. neg. neg.
I-6 neg. neg. neg. neg. neg.
Results expressed as Ct and transferred to negative (neg.) according to the cut-
off Ct$38 described by Toussaint et al. (2007).
I, immunized mice. C, nonimmunized mice.
{, death mice.
doi:10.1371/journal.pone.0034735.t001
Figure 3. Expression of VP2, VP7, and NS1 proteins in High five
cells infected with rBAC-VP2, rBAC-VP7, or rBAC-NS1. High five
cells were infected with rBAC-VP2, rBAC-VP7, or rBAC-NS1 and the
expression of the proteins was analysed at 24, 48 and 72 hours by
western blot using a mouse polyclonal antibody against BTV-4. The
position of the three proteins is indicated by an arrow.
doi:10.1371/journal.pone.0034735.g003
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VP7/rMVA-NS1 (Fig. 4A). There were no specific antibody
responses in non-immunized mice (Fig. 4B).
In addition, the presence of neutralizing antibodies against BTV
in the sera of immunized and non-immunized mice was analyzed
by virus neutralization tests. Neutralizing antibodies against BTV-
4 were observed in immunized mice 2 weeks after booster
treatment with rMVA-VP2, rMVA-VP7, and rMVA-NS1 with a
Log VNT
50 of 1.5360.15 (Fig. 4C). Neutralizing antibodies
against heterologous BTV-1 and BTV-8 were not observed in the
serum of immunized mice (VNT
50#0.3) at the time analyzed. In
addition, neutralizing antibodies against BTV-4, BTV-1, and
BTV-8 were not detected in sera from mice immunized with
pcDNA3-VP2, pcDNA3-VP7, and pcDNA3-NS1 at 14 days post-
immunization and in the non-vaccinated mice.
Heterologous prime boost vaccination with pcDNA3/
rMVA expressing VP2, VP7, and NS1 induces the
generation of specific T cell responses
We also determined the ability of the triple vaccine formulation
to elicit specific T cell responses by intracellular cytokine staining.
Whole splenocytes were restimulated with the individual BTV
antigens VP2, VP7, and NS1 for 72 h and intracellular IFNc
production by CD8+ T cells was then determined by flow
cytometry upon treatment of the cells with the golgi inhibitor,
brefeldin A,. VP2, VP7 and NS1 induced the expression of IFNc
by CD8+ T cells upon restimulation (Fig. 5), indicating that all 3
antigens are capable of inducing the activation of CTLs in vivo.
Cytokine responses in IFNAR
(2/2) mice after
immunization
To further analyze the ability of the pcDNA3 and rMVA-based
combination vaccine to induce an immune response in the host,
three adult IFNAR
(2/2) mice were immunized first with pcDNA3
or pcDNA3-VP2, pcDNA3-VP7 and pcDNA3-NS1, and two
weeks later with a booster of MVA or rMVA-VP2, rMVA-VP7
and rMVA-NS1, respectively. The presence in serum of the
cytokines IL-1b, IL-6, TNF-a, and IL-12 was analyzed at day 14,
21 and 28 post-immunization with DNA, by multiplex cytokine
Figure 4. Humoral immune response observed in IFNAR
(2/2)
mice vaccinated with heterologous prime boost vaccination
with pcDNA3 and rMVA expressing VP2/VP7/NS1. The presence
of antibodies specific of VP2, VP7, and NS1 in serum of immunized (A)
and non-immunized (B) IFNAR
(2/2) mice was analyzed by ELISA. Sera
from mice immunized with pcDNA3-VP2,-VP7,-NS1 (day 0) and rMVA-
VP2,-VP7,-NS1 (day 14) and non-immunized were collected at days 0,
14, and 28 before the challenge with BTV-4, and dilution 1:50 was
analyzed by ELISA as described in Materials and Methods. Standard
deviations are shown as error bars. (C) BTV-4 neutralizing antibody
detection in VP2/VP7/NS1 immunized mice by VNT. Neutralization titers
at day 28 in sera of animals immunized with pcDNA3-VP2,-VP7,-NS1
(day 0) and rMVA-VP2,-VP7,-NS1 (day 14) (&) and non-immunized (N)
are shown. Means are presented (3) and standard deviations are
shown as error bars.
doi:10.1371/journal.pone.0034735.g004
Figure 5. Intracellular staining of IFN-c, in T CD8+ cells of DNA/
rMVA-VP2/VP7/NS1 immunized IFNAR(2/2) mice. Two weeks
after second immunization spleens were harvested and the splenocytes
were stimulated with 10 mg/ml of recombinant VP2, VP7 or NS1
proteins. At 72 h post-stimulation, intracellular IFN-c production was
analysed in CD8-positive cells by flow cytometry. Results were
compared with those of a non-immunized mouse. Grey bars: non-
immunized mice; black bars: immunized mice. C-: unrelated stimulus,
NS3 BTV protein. The results represent the average of 6 mice 6 SD.
Asterisks represent significant difference between samples, calculated
by Man-Whitney non parametric test (p#0.01).
doi:10.1371/journal.pone.0034735.g005
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at the analyzed times. In contrast the presence of IL-1b
(1364.9 pg/ml), IL-6 (11.567.5 pg/ml), and IL-12
(54.168.7 pg/ml) was observed in the sera at day 14 after
immunization with pcDNA containing or not VP2, VP7, and NS1
from BTV-4 (Fig. 6). After the booster with rMVA, the levels in
serum of IL-1b and IL-6 were maintained or slightly decreased,
whereas the IL-12 levels were slightly increased at days 21 and 28
(68.1631.1 and 62.6622.7 pg/ml, respectively) (Fig. 6). All these
data support the stimulation of cellular response by the DNA and
MVA used as vaccine vectors increasing the efficacy of the
vaccines in addition of the BTV antigens.
Co-transfection of pcDNA3-VP2, pcDNA3-VP7 and
pcDNA3-NS1 generates aggregates of the three BTV
proteins
Particulate immunogens are the best for stimulating both
humoral and cellular immune responses [27]. The protein NS1
from BTV forms distinct tubular aggregates in infected or
transfected cells. The co-expression of NS1 with VP7 and VP2
could generate aggregates of the three antigens improving the
vaccination efficacy. To confirm this possibility BHK-21 cells were
transfected with different combinations of pcDNA3-VP2,
pcDNA3-VP7, and pcDNA3-NS1 using Lipofectamine 2000
Reagent. After 24 hours, the pattern of expression of the three
BTV proteins was analysed by immunofluorescence microscopy
using specific BTV-4 antibodies. Fluorescence distributed home-
genously in the cytoplasm was observed on BHK-21 cells
transfected with pcDNA3-VP2, pcDNA3-VP7, and pcDNA3-
VP2+pcDNA3-VP7. In contrast, cells transfected with pcDNA3-
NS1 showed a corpusculated signal indicating the aggregation of
NS1. Similarly, when NS1 was coexpressed with VP2, VP7 or
both antigens, the majority of the signal was also observed in
corpusculated forms (Fig. 7A). To confirm that VP2 and VP7 were
located in the aggregates generated by NS1, monoclonal
antibodies especific for VP2 and VP7 were used in immuno-
fluorencence assays. The results showed that VP2 and VP7 were
part of the NS1 aggregates (Fig. 7B) suggesting that the expression
of NS1, VP2, and VP7 in the vaccinated animals would generate
particulated immunogens that stimulate a better humoral and
cellular immune response against BTV.
Prime boost vaccination with pcDNA3-VP2/pcDNA3-VP7/
pcDNA3-NS1 and rMVA-VP2/rMVA-VP7/rMVA-NS1
protects IFNAR
(2/2) mice against heterologous BTV-8
and BTV-1 infection
Protein NS1 from BTV shares a high identity in its amino acid
sequence among BTV serotypes. The conservation in the
sequence of this protein suggests that the strategy of immunization
based on VP2, VP7 and NS1 from BTV-4 could also protect
against heterologous serotypes. In order to evaluate whether the
vaccination strategy based on pcDNA3/rMVA expressing VP2,
VP7, and NS1 proteins from BTV-4 also confers protection
against heterologous BTV infection, vaccinated IFNAR
(2/2) mice
were challenged with lethal doses of BTV-8 or BTV-1. Immunized
and control IFNAR
(2/2) mice were challenged subcutaneously
with 10
2 PFUs of BTV-8 or BTV-1. 100% of the immunized
animals were completely protected against the lethal challenge
with BTV-8 while 84% survived to the challenge with BTV-1. In
contrast, all the non-immunized mice died after challenge with
BTV-8 at day 5 and 6 post-infection, or with BTV-1 at day 6 and
7 post-infection, as expected (Fig. 8A). The titers of infectious virus
recovered in the blood after challenge with BTV-8 or BTV-1 were
Figure 6. Cytokine responses in IFNAR
(2/2) mice after immu-
nization. Sera from mice immunized with pcDNA3-VP2,-VP7,-NS1 (day
0) and rMVA-VP2,-VP7,-NS1 (day 14) (solid symbols) or pcDNA3 (day 0)
and MVA (day 14) (symbols) were collected at days 0, 14, 21, and 28.
The levels of cytokines were evaluated by a multiplex fluorescent bead
immunoassay for quantitative detection of 5 mouse cytokines
(Millipore’s MILLIPLEX Mouse Cytokine kit). Samples were analyzed
with a Luminex 2010 (Luminex Corporation). Means are presented (3).
doi:10.1371/journal.pone.0034735.g006
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(2/2) mice
by plaque assay (Fig. 8B). No infectious viruses were detected in
the immunized mice after challenge with BTV-8; however, a titer
of 9610
2 PFU/ml was observed in one BTV-1 infected mouse at
7 days post-challenge. The presence of the BTV genome in blood
of immunized and non-immunized IFNAR
(2/2) mice challenged
with BTV-8 and BTV-1 was analyzed by RT-qPCR to detect
possible virus replication that can not be determine by plaque
assay due to the low sensibility of the assay (Table 2). Non-
immunized mice (n=4) were positive for BTV genome at day
three after BTV-8 or BTV-1 infection and the presence of BTV
genome increased thereafter until the death of the animal, as was
observed in non-immunized mice infected with BTV-4. In
contrast, the RT-qPCR reaction yielded no positive results for
the majority of the immunized mice (n=6) challenged with BTV-8
at all days post-challenge analyzed (Ct$38). Viral genomes were
detected in two of the vaccinated mice (Ct=37) at day five post-
challenge. However, in these two immunized mice the Ct value
was higher than in the non-immunized mice and the presence of
BTV-genomes reverted to negative at day 7 post-challenge.
Similar results were observed in the immunized mice (n=6)
challenged with BTV-1, except one mouse that was positive at day
5 post-infection and the presence of BTV genome increased
thereafter until the death of the animal. Overall, these data show
that vaccination with pcDNA3/rMVA expressing VP2, VP7, and
NS1 proteins from BTV-4 exerts protective heterotypic immunity
against heterologous infection with BTV-8 or BTV-1.
Discussion
The development of recombinant bluetongue vaccines that are
inherently safe and compatible with a DIVA (differentiating
infected from vaccinated animals) approach has been the subject
of research over the last two decades. Vectored vaccines expressing
Figure 7. Co-expression of the VP2, VP7 and NS1 BTV proteins. (A) Immunofluorescence microscopy using a mouse polyclonal antibody
against BTV-4 in BHK-21 cells transfected with pcDNA3-VP2, pcDNA3-VP7, pcDNA3-NS1 and different combinations of these plasmids. (B)
Immunofluorescence microscopy using a mouse polyclonal antibody against BTV-4, or monoclonal antibodies against VP2 and VP7 from BTV-4 in
BHK-21 cells transfected with pcDNA3-VP2,-VP7,-NS1.
doi:10.1371/journal.pone.0034735.g007
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activation and reduce the number of multiserotype vaccinations
required, therefore providing a cost-effective product. Recent
recombinant DNA technology has provided novel approaches to
develop marker and safe vaccines against BTV. We have
engineered naked DNAs and recombinant modified vaccinia virus
Ankara (rMVA) expressing VP2, VP7 and NS1 proteins from
BTV-4. IFNAR
(2/2) mice inoculated with DNA/rMVA-VP2,-
VP7-NS1 in an heterologous prime boost vaccination strategy
generated significant levels of antibodies specific of VP2, VP7, and
NS1, and also neutralizing antibodies against BTV-4. In addition,
vaccination stimulated specific CD8
+ T cell responses against these
three BTV proteins. Significantly, the vaccine combination
expressing NS1, VP2 and VP7 proteins of BTV-4 elicited sterile
protection against a lethal dose of homologous BTV-4 infection.
Importantly, the vaccine induced cross-protection against lethal
doses of heterologous BTV-8 and BTV-1. These results demon-
strate that the rational design of vaccine formulations against BTV
can promote a multipronged protection that is effective across
serotypes.
IFNAR
(2/2) mice, a small animal model of BTV, AHSV, and
epizootic hemorrhagic disease virus (EHDV) infection [14,28,29],
has been used in the present work in order to facilitate the studies
of protection and immune response conferred by the heterologous
prime boost vaccination with DNA and rMVA expressing BTV-4
proteins. Obviously, no experimental mouse model can faithfully
capture all aspects of the complex interplay between virus and
target host species; however the IFNAR
(2/2) adult mouse model
has been previously used to investigate the determinants of BTV
virulence [30], and to evaluate the protection conferred by BTV
and AHSV vaccines [13,14,29]. Therefore, our results have
important preclinical applications prior to further characterization
of the vaccine formulation described herein in the physiological
viral host.
Both, neutralizing antibodies [16] and cytotoxic T lymphocytes
(CTL) play a role in protective immunity against BTV [19],
althought cellular immunity is likely to be crucial to protect against
a broad spectrum of BTV serotypes. The rationale for developing
DNA vaccines is to deliver the antigen into the MHC class I-
processing pathway for the induction of CTLs. On another hand,
MVA modulates host immune responses after infection of
immature human monocyte-derived dendritic cells [31] by
increasing IL-12, IFN-b, TNF-a and IL-6 levels, and Toll-like
receptor pathways [32] tending to induce specific CD8+ T cell and
strong humoral responses [33]. Our results show that immunizing
IFNAR
(2/2) mice with empty DNA/rMVA or DNA/rMVA-
VP2,-VP7,-NS1 significantly increased their levels of IL-12, IL-1b,
and IL-6 in serum. This cytokine response induced by the vaccine
vectors fit with the host response induced by BTV infection in
Figure 8. Protection of VP2, VP5 and VP7 vaccinated IFNAR
(2/2)
mice against lethal BTV-4, BTV-8, and BTV-1 challenges. Mice
(8 weeks old, 6 per group) were immunized twice by heterologous prime
boost vaccination with DNAs and rMVAs expressing VP2, VP7, and NS1
BTV-4 proteins (immunized, black line) or pcDNA3 and MVA (non-
immunized, dotted line), administered 2 weeks apart. Two weeks after
immunization mice were intravenously inoculated with 100 PFUs (lethal
dose) ofBTV-8(&) or BTV-1(N). (A)Survival rates of immunized andnon-
immunized IFNAR
(2/2) mice after inoculation with BTV-8 or BTV-1. The
mice were observedevery 24 h for12 days.(B)Titersof BTV-8(&)o rB T V -
1(N) recovered in blood of immunized and non-immunized IFNAR
(2/2)
mice after challenge. Virus was extracted from blood and determined as
described in Materials and Methods. Each point represents the mean
values of the viral titer of six animals, and standard deviations are shown
as error bars.
doi:10.1371/journal.pone.0034735.g008
Table 2. Detection of BTV RNA in blood of immunized and
non-immunized IFNAR
(2/2) mice after challenge with BTV-8 or
BTV-1 by RT-qPCR_S5.
Animals Infection Days post-challenge
3 579 1 1
C-1 BTV-8 31,21 {
C-2 BTV-8 35,67 24,89{
C-3 BTV-8 32,06 {
C-4 BTV-8 37,16 25,06 {
I-1 BTV-8 neg. 36,93 neg. neg. neg.
I-2 BTV-8 neg. neg. neg. neg. neg.
I-3 BTV-8 neg. neg. neg. neg. neg.
I-4 BTV-8 neg. neg. neg. neg. neg.
I-5 BTV-8 neg. 37,09 neg. neg. neg.
I-6 BTV-8 neg. neg. neg. neg. neg.
C-5 BTV-1 32,05 27,33 23,15{
C-6 BTV-1 31,54 26,84 22,98 {
C-7 BTV-1 36,15 28,52 {
C-8 BTV-1 28,92 25,06 {
I-7 BTV-1 neg. neg. neg. neg. neg.
I-8 BTV-1 neg. neg. neg. neg. neg.
I-9 BTV-1 neg. 37,09 26,81 {
I-10 BTV-1 neg. 37,68 neg. neg. neg.
I-11 BTV-1 neg. neg. neg. neg. neg.
I-12 BTV-1 neg. 36,63 neg. neg. neg.
Results expressed as Ct and transferred to negative (neg.) according to the cut-
off Ct$38 described by Toussaint et al. (2007).
I, immunized mice. C, nonimmunized mice.
{, death mice.
doi:10.1371/journal.pone.0034735.t002
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1b, and IL-6 are up-regulated [34]. The fact that the antiviral host
response induced by the vaccine vectors was similar to that
induced by infection with BTV supports the suitability of using
DNA and rMVA in the development of recombinant BTV
vaccines.
Previous work showed that IFNAR
(2/2) mice immunized with
DNA/rMVA-VP2,-VP5,-VP7 produced good levels of neutraliz-
ing antibodies against BTV-4, induced a T cell response, and
conferred sterile protection to the IFNAR
(2/2) mice against an
homologous challenge with BTV-4 [14]. In contrast, this vaccine
composition did not conferred good protection against heterolo-
gous challenges with BTV-8 (unpublished results). In order to
develop a BTV vaccine that generates cross-protection against
several BTV serotypes, the protein NS1 was included in the
vaccine composition. NS1 is one of the most conserved proteins
amongst BTV serotypes [35]. Furthermore, studies with recom-
binant vaccinia virus expressing BTV proteins to map the location
of epitopes recognized by CTLs from Australian merino sheep
showed that NS1 was recognized by CTL from all sheep [23]. In
addittion, the NS1 gene product on its own assembles into tubules
[36] and particulate immunogens are the best for stimulating both
humoral and cellular immune responses [27]. Vaccine particulates
mimic physiological antigen presentation and create much higher
local antigen concentrations than soluble antigen. Additionally,
aggregates are protected from degradation, which allows them to
remain intact for interaction with antigen-presenting cells and
their internalization to appropriate MCH class II-loading
compartments, effectively enhancing their presentation of T cells.
This therefore results in stronger T cell responses and B cell help,
and the overall induction of a stronger immune response
[37,38,39]. Previous work demostrated that the recombinant
tubules were efficiently taken up by antigen-presenting cells and
were able to reach the major histocompatibility complex (MHC)
class I pathway [40]. The present work shows that the co-
expression of VP2, VP7 and NS1 in transfected BHK-21 cells
generates aggregates containing the three BTV proteins. This
result suggests that in animals immunized with this three proteins
particulate immunogens would be generated due to the presence
of NS1 that would stimulate a stronger humoral and cellular
immune response against BTV, improving the vaccine efficacy.
We now show that IFNAR
(2/2) mice immunized with DNA/
rMVA-VP2,-VP7,-NS1 produced levels of neutralizing antibodies
against BTV-4 similar to those of animals immunized with DNA/
rMVA-VP2,-VP5,-VP7 [14], and intracellular cytokine staining
showed that VP2, VP7 and NS1 induced the activation of CTLs in
vivo. In addition, 100% of the DNA/rMVA-VP2,-VP7,-NS1
vaccinated animals survived to the challenge with BTV-4 and
viremia was not observed in the immunized animals after BTV-4
challenge. These results indicate that the heterologous prime boost
vaccination with DNA/rMVA-VP2,-VP7,-NS1 confers sterile
protection against an homologous challenge with BTV-4 in
IFNAR
(2/2) mice, as previously observed with DNA/rMVA-
VP2,-VP5,-VP7. Interestingly, the vaccination strategy described
herein also protected against an heterologus challenge with BTV-1
or BTV-8. Our results show that the inclusion of NS1 in the
vaccine composition induces an heterotypic cellular immune
response that protects against heterologous BTV infections. There
is some evidence of partial cross protection against phylogeneti-
cally related serotypes [41]. However, this is the first potential
recombinant vaccine against BTV that cross-protects against
serotypes that are not related phylogenetically. In addition, this
immunization strategy contains DIVA properties. Antibodies
against VP2, VP7, and NS1, but not against the other BTV
proteins are detected in the sera of DNA/rMVA-VP2,-VP7,-NS1
immunized mice. Recently, a promising marker vaccine was
generated by reverse genetics based on BTV-1 with deletions in
the essential gene that encodes the VP6 [15]. This vaccine was
safe, because it is based on a replication competent and
propagation deficient virus, DIVA, and highly protective, but
only against homologous challenge. In addition, although VLPs
were safe and good DIVA monovalent vaccines against single
BTV serotypes when they were used as bivalent immunogens
combining BTV-1 and BTV-4, VLPs only protected against BTV-
1 probably due to a interference in protective response to BTV-4
[42]. This work raises the question of whether the combinations
based on VLPs or inactivated virus could be used as multivalent
BTV vaccines. Our results show that the strategy of immunization
based on DNA and rMVA expressing VP2, VP7, and NS1 of
BTV-4 is the first effective approach to generate a multivalent
vaccine against BTV.
In summary, we have developed a marker vaccine and a
vaccination strategy against several BTV serotypes based on
heterologous prime boost vaccination using DNA and rMVA
expressing VP2, VP7, and NS1 proteins of BTV-4. Although
further characterization of this vaccine formulation in the virus
natural host will be necessary, the data from the IFNAR
(2/2)
mouse model suggest that the DNA/rMVA-VP2,-VP7,-NS1
marker vaccine could be a promising vaccine against multiple
serotypes of BTV.
Materials and Methods
Virus and cells
Baby hamster kidney (BHK-21), chicken embryo fibroblast (DF-
1), and Vero cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 2 mM glutamine and 10%
fetal calf serum (FCS). Insect cells High Five (Invitrogen) were
grown in TC-100 medium supplemented with 10% FCS. BTV
serotype 4 (Spain/01) (BTV-4), BTV serotype 8 (Belgium/08)
(BTV-8), and BTV serotype 1 (ALG2006/01) (BTV-1) were used
in the experiments. Standard virus titrations were performed in
Vero cells. Virus stocks were generated by infection of confluent
BHK-21 cells using a multiplicity of infection (MOI) of 1. At
48 hours post-infection (h.p.i.), or when total cytopathic effect
(CPE) was visible, the cells and supernatants were harvested and
centrifuged. The virus were released from the cells by three freeze
and thaw cycles. Modified vaccinia virus Ankara (MVA) was
growth and titered in DF-1 cells using a MOI of 1.
Mice
IFN a/bR
o/o IFNAR
(2/2) mice, on a 129 background were
purchased from B&K Universal Ltd. Eight-week old male mice
were used throughout. Mice were maintained under pathogen-free
conditions and allowed to acclimatize to the biosafety level 3
(BSL3) animal facility at the Centro de Investigacio ´n en Sanidad
Animal, INIA, Madrid, for 1 week before use in our experiments.
All experiments with live animals were performed under the
guidelines of the European Community (86/609) and were
approved by the ethical review committee at the Centro de
Investigacio ´n en Sanidad Animal of the Instituto Nacional de
Investigaciones Agrarias (CISA-INIA).
Cloning of NS1 BTV-4 gene and generation of
recombinant MVA
Segment 5 corresponding to NS1 was amplified from BTV
serotype 4 (Spain/01). To generate pcDNA3-NS1 and the MVA
transfer plasmid pSC11-NS1, the restriction site SmaI was
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oligonucleotide primers BTV-4-NS1-SmaI (1) VS (59-CGC CCG
GGA TGG AGC GCT TTT TGA GAA AAT AC-39), and BTV-
4-NS1-SmaI (1659) RS (59-CGC CCG GGC TAA TAC TCC
ATC CAC ATC TG-39, Sma I site underlined), were used to
generate a PCR product comprising BTV-4 gene NS1. PCR
products were digested with SmaI and cloned into the SmaI
digested pSC11 plasmid or EcoRV digested pcDNA3 plasmid to
generate pSC11-NS1 and pcDNA-3-NS1, respectively. The
generated plasmids were sequenced to analyze the right orienta-
tion of the cloned NS1 gene.
The MVA transfer plasmid pSC11-NS1 contained the NS1
BTV gene inserted into the thymidine kinase site of MVA and
under the control of the vaccinia virus (VV) early/late promoter
p7.5. Recombinant MVA (rMVA) were prepared by infecting DF-
1 cells with MVA at a multiplicity of infection of 1 (MOI=1) and
transfecting them with the transfer plasmid pSC11-NS1. Cell
cultures were harvested at 48 h.p.i., and the rMVA were selected
after plaque assay by the addition of X-Gal to the agar overlay.
rMVA was cloned four times by plaque isolation assay and the
purity of the rMVA-NS1 analyzed by PCR by using the
oligonucleotide primers used to amplify the BTV gene and
described above.
The plasmids pcDNA3-VP2 and pcDNA3-VP7, and the
rMVA-VP2 and rMVA-VP7 have been previously described [14].
Generation of recombinant baculovirus (rBAC)
To generate rBAC-NS1, the plasmid pcDNA3-NS1 was
digested with EcoRI and Xba I and the BTV genes were cloned
in the EcoRI and Xba I digested pFastBac-HT-C in order to
generate the transfer plasmid pFastBac-HT-C-NS1.
After the generation of the transfer plasmids pFastBac-HT-C-
NS1, the recombinant baculovirus rBAC-NS1 was generated by
using the Bac-to-Bac Baculovirus Expression System (Invitrogen),
according to the method recommended by the manufacturer.
rBAC-NS1 was used to express recombinant NS1 protein from
BTV-4 in High five cells. These proteins were purified using the
ProBond Purification System (Invitrogen) following the procedure
indicated by the manufacturer for protein purification under
denaturing conditions. After purification, denatured NS1 was
dialyzed overnight in PBS to refold the native structure of the
protein.
Recombinant BAC-VP2 and BAC-VP7 were generated as
described by Calvo-Pinilla et al. [14].
Immunoblotting
HighFive cell lysates were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (10% polyacrylamide). The
proteins were transferred to a nitrocellulose membrane with a Bio-
Rad Mini Protean II electroblotting apparatus at 150 mA for 1 h
in 25 mM Tris-192 mM glycine buffer (pH 8.3) containing 20%
methanol. Membrane binding sites were blocked for 1 h with 5%
dried skim milk in TBST (20 mM Tris-HCl [pH 7.5], 150 mM
NaCl). The membranes were then incubated with a mouse
monoclonal antibody specific for Hys (GE). Bound antibody was
detected with horseradish peroxidase-conjugated rabbit anti-
mouse antibody and the ECL detection system (Amersham
Pharmacia Biotech.).
Detection of antibodies against VP2, VP7 and NS1 by
ELISA
MaxiSorp plates (Nunc, USA) were coated with VP2, VP7, or
NS1 purified baculovirus expressed proteins (164 ng per well) and
incubated overnight at 4uC. Plates were saturated with blocking
buffer (PBS-0.05% Tween 20 and 5% skim milk). The animal sera
diluted in blocking buffer were added and incubated for 1 hour at
37uC. After three washes in PBS-0.05% Tween 20, plates were
incubated for 1 hour at 37uC with an anti-mouse-HRP secondary
antibody (Biorad, USA) at a 1/2,000 dilution in blocking buffer.
Finally, after three washes in PBS-0.05% Tween 20, the reaction
was developed with 50 ml of substrate solution 3,39, 5,59–
tetramethylbencidine liquidsupersensitive (TMB) (Sigma) and
stopped by adding 50 mlo f3 NH 2SO4. Results were expressed
as optical densities (ODs) measured at 450 nm.
Quantification of cytokines in murine sera
IL-12 (p70), IL-6, IL1-b, and TNF were quantified in the sera
using the Millipore’s MILLIPLEX Mouse Cytokine kit following
the procedures indicated by the manufacturer. Samples were
analyzed with a Luminex 2010 (Luminex Corporation).
Immunofluorescence
Cells were plated on glass coverslips and they were infected or
transfected. Infections were performed at an MOI of 1 PFU/cell
at 37uC in DMEM containing 2% FCS. Free viruses were
removed after 90 minutes and the cells were maintained in
DMEM 2% FCS. Transfections were performed with lipofectamin
2000 (Invitrogen) with 4 mg of DNA, according to the method
recommended by the manufacturer. At the indicated times, the
cells were washed with PBS and fixed by addition of 4%
paraformaldehyde for 30 min at room temperature. Cells were
incubated with a PBS-FCS 20% diluent containing 0.2% Saponin
(Superfos-Biosector, Vedback, Denmark) for 1 hour at room
temperature. Mouse polyclonal antibody specific for BTV-4 was
allowed to adsorb for 90 min at room temperature, and washed
three times with PBS-FCS 2%. Cells were then incubated for
30 min at room temperature with an anti-mouse secondary
antibody conjugated to Alexa 488. The coverslips were washed
five times with PBS-FCS 2%, mounted on glass slides, and
analyzed with a Olympus CKX41 microscope.
Prime boost immunization and challenge with BTV in
IFNAR
(2/2) mice
Groups of six IFNAR
(2/2) mice were immunized by heterolo-
gous prime boost vaccination with DNAs and rMVAs expressing
BTV-4 proteins or pcDNA3 and MVA (non-immunized mice),
administered 2 weeks apart. A suspension of 50 mg of each pcDNA3
construct was administered intramuscularly and 10
7 PFUs of each
rMVA construct wereinoculated intraperitoneally. Two weeks after
immunization all mice were subcutaneously inoculated with
10
3 PFUs of BTV-4, or 10
2 PFUs of BTV-8, or 10
2 PFUs of
BTV-1 (lethal doses) [13]. Mice were bled before each immuniza-
tion and virus challenged. Sera were tested for BTV-4 neutralizing
antibodies by a Virus Neutralization Test (VNT).
Detection of BTV-4, BTV-8, and BTV-1 in blood
Whole blood was collected in EDTA from all animals at regular
intervals after inoculation. The viruses were released from whole
blood by three freeze/thaw cycles. The amount of infectious virus
was measured by plaque assay on Vero cells or RT-qPCR specific
for BTV segment 5.
BTV-4 neutralizing antibody detection in immunized
mice by VNT
The VNT was used to determine neutralizing antibody titers
against BTV-4. For plaque reduction assays, 2 fold dilutions of
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37uC and then plated onto monolayers of Vero cells. After 1 hour,
agar overlays were added and the plates were incubated for 5 days.
The titer was determined as the highest dilution that reduced the
number of plaques by 50%.
RT-qPCR specific for BTV segment 5
Whole blood was collected in EDTA from all animals at regular
intervals after inoculation and BTV challenge. Total RNA was
extracted from blood with TRI Reagent Solution (Ambion),
according to the method recommended by the manufacturer. The
real-time RT-qPCR specific for BTV segment 5 was performed as
described by Toussaint et al. [43].
FACS analysis
Two weeks after booster immunizations, 10
6 splenocytes were
restimulated with 10 mg/ml of recombinant VP2, VP7 or NS1
proteins or left untreated in the presence of 1 ml/ml of GolgiPlug
(BD Biosciences) for the last 6 h of stimulation. At 72 h post-
stimulation, the cells were washed with PBS+1%FCS and surface-
labelled with a FITC-conjugated anti-CD8 mAb (BD Biosciences)
on ice for 30 min. Nonspecific binding of the mAb was blocked by
preincubating the cells with Fc Block (2.4G2; BD Biosciences).
Intracellular staining for IFNc (PE-conjugated anti-IFNc mAb;
BD Biosciences) was then performed using the BD Cytofix/
Cytoperm Fixation/Permeabilization Kit (BD Biosciences) ac-
cording to the manufacturer’s instructions. Flow cytometry data
were collected on an LSR II flow cytometer running the Diva
Software (BD Biosciences) and analyzed with FlowJo version 8.6
for MacOS (TriStar).
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